Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Janux Therapeutics, Inc.

NASDAQ: JANX · Life Sciences · 2 alerts · CIK 1817713

Share price
$10.92Close, Nov 16
Market cap
$668M
Shares outstanding
61.18MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Janux Therapeutics, Inc. filings on SEC EDGAR ↗

4:23 PM ET 10-Q
Financial Results

Janux Therapeutics Q3 2026 Results: Net Loss of $21.6M, Loss Narrows

Janux Therapeutics reported a net loss of $21.6 million for the third quarter of 2026, an improvement from the $24.3 million loss in the prior year period. The company maintains a strong liquidity position with $945.7 million in cash, cash equivalents, and short-term investments as of September 30, 2026.

Key figure
Net loss $21.6M
4:11 PM ET 8-K
Financial Results

Janux Therapeutics Financial Results

Janux Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting a strong cash position of $945.7 million. The company continues to advance its clinical pipeline, including dosing the first patient in a Phase 1 study of JANX013 and preparing for an upcoming data presentation for JANX011.

“During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007. We are also preparing to present initial clinical data from JANX011 on November 9. JANX011 was designed to achieve deep B-cell depletion while limiting cytokine release. The upcoming clinical update will provide an initial look at how this differentiated approach translates into humans.”

David Campbell, Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.